JP2005529587A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529587A5
JP2005529587A5 JP2003576000A JP2003576000A JP2005529587A5 JP 2005529587 A5 JP2005529587 A5 JP 2005529587A5 JP 2003576000 A JP2003576000 A JP 2003576000A JP 2003576000 A JP2003576000 A JP 2003576000A JP 2005529587 A5 JP2005529587 A5 JP 2005529587A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
binding
composition
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/007647 external-priority patent/WO2003077947A1/en
Publication of JP2005529587A publication Critical patent/JP2005529587A/ja
Publication of JP2005529587A5 publication Critical patent/JP2005529587A5/ja
Pending legal-status Critical Current

Links

JP2003576000A 2002-03-15 2003-03-13 Ｃｄ２００レセプターを調節する方法 Pending JP2005529587A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36451302P 2002-03-15 2002-03-15
PCT/US2003/007647 WO2003077947A1 (en) 2002-03-15 2003-03-13 Methods of modulating cd200 receptors

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2006058745A Division JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134635A Division JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134634A Division JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Publications (2)

Publication Number Publication Date
JP2005529587A JP2005529587A (ja) 2005-10-06
JP2005529587A5 true JP2005529587A5 (OSRAM) 2006-04-20

Family

ID=28041929

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003576000A Pending JP2005529587A (ja) 2002-03-15 2003-03-13 Ｃｄ２００レセプターを調節する方法
JP2006058745A Pending JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134635A Withdrawn JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134634A Withdrawn JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006058745A Pending JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134635A Withdrawn JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134634A Withdrawn JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Country Status (16)

Country Link
US (3) US20030223991A1 (OSRAM)
EP (3) EP2322218A1 (OSRAM)
JP (4) JP2005529587A (OSRAM)
AT (1) ATE439861T1 (OSRAM)
AU (3) AU2003220219A1 (OSRAM)
CA (1) CA2478803A1 (OSRAM)
CY (1) CY1109521T1 (OSRAM)
DE (1) DE60328870D1 (OSRAM)
DK (1) DK1482973T3 (OSRAM)
ES (1) ES2330211T3 (OSRAM)
MX (1) MXPA04008937A (OSRAM)
NZ (2) NZ570998A (OSRAM)
PT (1) PT1482973E (OSRAM)
SI (1) SI1482973T1 (OSRAM)
WO (1) WO2003077947A1 (OSRAM)
ZA (2) ZA200407384B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177295A1 (en) * 1999-05-13 2002-02-06 Medical Research Council Ox2 receptor homologs
ATE423571T1 (de) * 2001-10-12 2009-03-15 Schering Corp Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
CA2487428A1 (en) * 2002-06-07 2003-12-18 Trillium Therapeutics Inc. Cd200-receptor mediated modulation of bone development
CA2511513A1 (en) * 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200
JP4919453B2 (ja) * 2005-04-07 2012-04-18 独立行政法人理化学研究所 炎症性疾患の予防又は治療剤
HUE030850T2 (en) 2006-06-16 2017-06-28 Univ Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of hair loss
KR20090094846A (ko) * 2006-12-22 2009-09-08 쉐링 코포레이션 Ｃｄ200ｒ에 대한 항체
EP2121015A4 (en) * 2007-01-11 2010-03-24 Boehringer Ingelheim Int CD200 AND RECEPTOR THEREFOR, CD200R AND BONE MASS MODULATION BY ESTEOKLASTENDIFFERENZIERUNG
WO2009004339A2 (en) * 2007-07-03 2009-01-08 Imperial Innovations Limited Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
EP2432805A1 (en) * 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat sepsis
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
MX342017B (es) 2010-03-26 2016-09-09 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN104619722B (zh) * 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
JP5854432B2 (ja) * 2012-09-28 2016-02-09 森永乳業株式会社 アレルギー反応検出法
EP4043493A1 (en) 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3154585B1 (en) 2014-06-11 2022-02-23 Kathy A. Green Use of vista agonists and antagonists to suppress or enhance humoral immunity
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
TW202216201A (zh) 2016-02-12 2022-05-01 比利時商楊森製藥公司 抗vista抗體及片段、其用途及鑑定其之方法
JP7184751B2 (ja) 2016-04-15 2022-12-06 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用
AR116668A1 (es) * 2018-09-14 2021-06-02 Lilly Co Eli Anticuerpos agonistas contra cd200r y sus usos

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5202267A (en) 1988-04-04 1993-04-13 Hygeia Sciences, Inc. Sol capture immunoassay kit and procedure
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
EP0469477B1 (en) * 1990-08-02 1995-09-20 F. Hoffmann-La Roche Ag Antiallergic combination
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5552284A (en) 1991-03-29 1996-09-03 Genentech, Inc. Detection of interleukin-8 receptors by nudeic acid hybridization
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
JP3888695B2 (ja) 1996-05-27 2007-03-07 株式会社医学生物学研究所 ヒトｌｅｃｔ２に対する抗体、それを産生する細胞、その測定法及び測定用キット
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JPH10212242A (ja) * 1996-11-27 1998-08-11 Tosoh Corp 新規血小板増多剤
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US5948627A (en) 1997-05-30 1999-09-07 One Lambda Immunobead flow cytometric detection of anti-HLA panel-reactive antibody
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
JPH11246435A (ja) * 1997-10-29 1999-09-14 Ajinomoto Co Inc 免疫調整剤
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
EP1100869A4 (en) * 1998-07-30 2005-04-27 Human Genome Sciences Inc 98 HUMAN SECRETED PROTEINS
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
EP1177295A1 (en) * 1999-05-13 2002-02-06 Medical Research Council Ox2 receptor homologs
AU2001278338A1 (en) * 2000-08-03 2002-02-18 David A Clark Methods and compositions for modulating tumor growth
US7186818B2 (en) * 2001-04-26 2007-03-06 Immunex Corporation DNA encoding soluble variants of human OX2 receptors
US7368535B2 (en) * 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
ATE423571T1 (de) * 2001-10-12 2009-03-15 Schering Corp Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
US20040126777A1 (en) * 2002-01-28 2004-07-01 Bhatt Ramesh Rajani Lp mammalian proteins; related reagents
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer

Similar Documents

Publication Publication Date Title
JP4964957B2 (ja) 抗薬物抗体アッセイ
RU2014104113A (ru) Elisa для vegf
JP2017524725A5 (OSRAM)
JP2023017841A5 (OSRAM)
RU2015155552A (ru) Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
RU2004136285A (ru) Способ диагностики гепатоцеллюлярной карциномы
JP2007527406A5 (OSRAM)
JP2016505634A5 (OSRAM)
JP2006502416A5 (OSRAM)
JP2008538919A5 (OSRAM)
RU2010117018A (ru) Антитела к gdf8 и их применения
JP2018535404A5 (OSRAM)
JP2010536043A5 (OSRAM)
RU2014128510A (ru) Способ определения свободного связывающего партнера мультиспецифичного связующего
JP2008545145A5 (OSRAM)
DK1125130T3 (da) Påvisning af syreresistente mikroorganismer i afföringen
RU2013109173A (ru) АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
Stevenson et al. Analysis of soluble HLA class II antigenic material in patients with immunological diseases using monoclonal antibodies
JP4413179B2 (ja) 免疫学的粒子凝集反応方法
JP5821198B2 (ja) 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法
JPWO2020158856A1 (ja) 生物学的試料中の遊離ａｉｍの免疫学的分析方法
WO2020158858A1 (ja) 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び対象におけるｎａｓｈの検出方法
Quinton et al. Toward the limits of sandwich immunoassay of very low molecular weight molecules
JPWO2020158857A1 (ja) 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び測定キット
CN104833797B (zh) 检测双特异性抗体msbody的elisa方法及应用